Quarterly report pursuant to Section 13 or 15(d)

Note 13 - Segment Information - Financial Information Relating to Reportable Segments (Details)

v3.21.2
Note 13 - Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Sep. 30, 2021
Sep. 30, 2021
Sep. 30, 2020
Net sales   $ 257,719 $ 204,199
Operating income   63,222 49,092
Costs recognized on sale of acquired inventory   (1,512) 0
Impact of partially owned consolidated subsidiaries   634 0
Restructuring costs [1]   (1,185)  
Corporate general, selling, and administrative expenses   (86,175) (72,598)
Diagnostics and Genomics [Member]      
Restructuring costs $ (1,200)    
Operating Segments [Member]      
Operating income   97,563 79,026
Costs recognized on sale of acquired inventory   (1,512) 0
Amortization of acquisition related intangible assets   (18,389) (15,501)
Impact of partially owned consolidated subsidiaries   1,562 0
Acquisition related expenses   2,377 (136)
Stock-based compensation, inclusive of employer taxes   (13,860) (13,333)
Restructuring costs   (1,185) 0
Operating Segments [Member] | Protein Sciences [Member]      
Net sales   197,186 154,446
Operating income   90,100 70,352
Operating Segments [Member] | Diagnostics and Genomics [Member]      
Net sales   60,985 50,125
Operating income   7,463 8,674
Intersegment Eliminations [Member]      
Net sales   (452) (372)
Corporate, Non-Segment [Member]      
Corporate general, selling, and administrative expenses   $ (210) $ (964)
[1] The charges recorded above are accrued within Other current liabilities as of September 30, 2021. There were no cash payments or adjustments to the initial accrual during the period ended September 30, 2021.